title: Staphylococcus aureus with decreased susceptibility to glycopeptides in cystic fibrosis patients.
abstract: We report the isolation of Staphylococcus aureus with decreased susceptibility to glycopeptides in five CF patients and review the clinical and microbiological features of these cases. Three patients presented with pulmonary exacerbation that may be attributed to these strains and two of them were successfully treated using linezolid therapy. Glycopeptide-intermediate S. aureus (GISA) strains isolated in two patients were susceptible to methicillin, while the three other patients harbored methicillin-resistant GISA. Rarely reported in CF, GISA may remain underestimated due to the difficulty of detection, and both clinicians and microbiologists should be aware of the GISA emergence in CF patients' population.
authors.affiliation: Centre Hospitalier Régional Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, Service de Pédiatrie générale, Maladies Infectieuses, Immunologie Clinique, 371, Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Filleron
authors.forename: Raphaël
authors.initials: R
authors.lastname: Chiron
authors.forename: Marie-Elisabeth
authors.initials: ME
authors.lastname: Reverdy
authors.forename: Hélène
authors.initials: H
authors.lastname: Jean-Pierre
authors.forename: Oana
authors.initials: O
authors.lastname: Dumitrescu
authors.forename: Linda
authors.initials: L
authors.lastname: Aleyrangues
authors.forename: François
authors.initials: F
authors.lastname: Counil
authors.forename: Estelle
authors.initials: E
authors.lastname: Jumas-Bilak
authors.forename: Hélène
authors.initials: H
authors.lastname: Marchandin
mesh_terms: D000081:Acetamides / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use; D002648:Child; D003550:Cystic Fibrosis / Q000382:microbiology*; D024881:Drug Resistance, Bacterial; D005260:Female; D006020:Glycopeptides / Q000627:therapeutic use*; D006801:Humans; D000069349:Linezolid; D008297:Male; D023303:Oxazolidinones / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D055815:Young Adult
chemical_list: D000081:Acetamides; D000890:Anti-Infective Agents; D006020:Glycopeptides; D023303:Oxazolidinones; D000069349:Linezolid